Will Someone Buy Pro Medicus (ASX:PME) At Any Price?

Will Someone Buy Pro Medicus (ASX:PME) At Any Price?

I'm on record as saying I think Pro Medicus is my favourite stock on the ASX. But the stellar share price run from around $1 five years ago to $33 today is truly stupendous. When we covered its results less than a year ago, we did not predict it would gain more than 200% in just one year.

read more

Fun Times With Ecofibre (ASX:EOF): FY 2019 Results Analysis And Valuation Meditation

Ecofibre (ASX:EOF) Full Year 2019 Results Analysis And Valuation Meditation

read more

Ecofibre (ASX:EOF) Quarterly Report Update Q4 FY 2019

Ecofibre (ASX:EOF) has performed strongly over the past few months since we initiated on the company in April (see here) – In that time the share price is up 52% and it’s up a total of 222% for investors fortunate enough to get into the March IPO.

read more

Is The Forager Australian Shares Fund (ASX:FOR) Undervalued?

I often get asked by investors for suggestions about investing in Exchange Traded Funds (ETFs) and Listed Investment Companies (LIC).

read more

Straker Translations Ltd (ASX:STG) Initiation Report And Analysis

Straker Translations Ltd (ASX: STG) listed with little fanfare in late October last year – essentially midway through the grinding Risk Off phase that impacted the Growth sector between the end of August and the Christmas period of 2018 (during which time many growth stocks were down 20-40% from their August highs). Floated at a price of $1.51 per share, the company debuted relatively strongly and reached a peak of $1.91 in the first few days of trading – but has spent the majority of the period since trading underwater versus its IPO price, and bottomed out below $1.20 in April – before recovering over the past couple of months (closing at $1.55 on Friday).

read more

Can Xref (ASX:XF1) Accelerate Revenue Growth?

Can Xref (ASX:XF1) Accelerate Revenue Growth?

Since Xref Ltd (ASX:XF1) released its quarterly results, we’ve seen an initially muted reaction, followed by a rising, then falling, share price. To me, that suggests that the market didn’t really know how to respond the results, which were “good enough” without being impressive.

read more

Laserbond: Impressions From A Site Visit

Laserbond (ASX:LBL): Guidance, Thesis Update And Site Visit

read more

My Portfolio Performance Update

Claude Walker's Portfolio Performance Update

I've recently been thinking a bit about whether my skills are most useful as a research analyst and investor, or if they are most useful as an analyst and writer. Although they are obviously related, it's possible that some analysts could be better off focusing purely on investing, while others are most valuable as communicators.

read more

The Gent Manifesto: My Journey And Investment Process

The Gent's Manifesto: My Journey And Investment Philosophy

read more

Why I'm Long Bigtincan Holdings Ltd (ASX:BTH)

Why I'm Long Bigtincan Holdings Ltd (ASX:BTH): Cracking America

Update 3/7/2019

Please note: The author of this piece, Matt Brazier, has decided to sell his Bigtincan Holdings for the following reasons:

read more